InvestorsHub Logo
Followers 416
Posts 52354
Boards Moderated 13
Alias Born 12/16/2001

Re: TREND1 post# 5059

Wednesday, 11/11/2020 5:14:30 PM

Wednesday, November 11, 2020 5:14:30 PM

Post# of 13372
Citing a spike in COVID-19 cases across clinical sites, Moderna (NASDAQ:MRNA) announces that the first interim analysis of results from the large-scale pivotal study, COVE, of vaccine candidate mRNA-1273 will include "substantially more" that the 53 cases it was expecting (the higher the number the better). Case accrual has been completed for the readout. The dataset is being prepared for submission to the independent Data Safety Monitoring Board.

Enrollment was completed on October 22.

The company remains blinded to the data.

The efficacy bar has been set by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). Their candidate, BNT162b2, showed 90% efficacy based on 94 confirmed cases.

Shares up 1% after hours.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News